VIDEO: AZR-MD-001 for MGD treatment shows promising study outcomes
Key takeaways:
- AZR-MD-001 0.5% for the treatment of meibomian gland dysfunction met the primary endpoints in a phase 2 trial.
- The ointment improved the signs and symptoms of MGD and was well tolerated.
SAN DIEGO — In this Healio Video Perspective from the ASCRS meeting, Preeya K. Gupta, MD, presents the results of the phase 2 trial of AZR-MD-001, an ointment for the treatment of meibomian gland dysfunction from Azura Ophthalmics.
“MGD is a highly prevalent condition. It’s frustrating for patients, frustrating for clinicians. To date, there has been no FDA-approved therapy in the prescription world for MGD,” she said.
AZR-MD-001 0.5% reached statistical significance in terms of improvement of signs and symptoms of MGD at 3 months, but improvement was seen as early as 2 weeks.
The ointment was well tolerated and has the advantage of requiring only two applications per week.
Collapse
Gupta PK. AZR-MD-001 efficacy in restoring gland function and improving signs and ocular symptoms of meibomian gland dysfunction (MGD): A phase 2 trial. Presented at: American Society of Cataract and Refractive Surgery meeting; May 5-8, 2023; San Diego.
Read more about